Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists

Caffeine Clinical Trial

Official title:

Consumption Status of Caffeine and Adverse Effects Experience Among Anesthetists

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05323578
• Other study ID #: R 66/2022
• Status: Completed
• Start date: April 18, 2022
• Est. completion date: July 15, 2022

Study information

• Verified date: September 2022
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

High-caffeine consumption has been increasing in physicians, frequently causing the most common symptoms such as tremor, insomnia, anxiety, and nervousness and rarely leading to serious adverse effects like seizure, acute mania, and stroke due to caffeine overdose. There have been no studies regarding analysis of high-caffeine consumption and its adverse effects among anesthetists.

Description:

This study was to examine high-caffeine consumption patterns, associated factors, and adverse effects based on responses anesthetists with different age of experience.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 168
• Est. completion date: July 15, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Years to 80 Years

Eligibility

Inclusion Criteria:

• Any anesthetist

Exclusion Criteria:

• Pregnancy

Related Conditions & MeSH terms

• Caffeine
• Caffeine Dependence
• Caffeine Withdrawal

Intervention

Other:
• Survey
Prevalence of safe caffeine consumption among anesthetists

Locations

Country	Name	City	State
Egypt	Ain Shams University Hospitals	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevalence of caffeine consumption among a sample of anesthesiologists, to determine their caffeine daily intake in relation to the safe level suggested by the European Food Safety Authority (EFSA).	Average daily amount of caffeine consumption in mg	24 hours
Primary	Subgroup comparison between junior and senior anesthetists	Average daily amount of caffeine consumption in mg	24 hours